MRNA Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

48.400

Open

46.635

VWAP

45.85

Vol

1.01M

Mkt Cap

18.22B

Low

44.550

Amount

46.20M

EV/EBITDA(TTM)

--

Total Shares

396.59M

EV

13.05B

EV/OCF(TTM)

--

P/S(TTM)

9.19

Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).

Show More

Events Timeline

(ET)

2026-05-01

09:00:00

Apple Stock Rises 3% Driven by Strong Earnings

2026-05-01

07:10:00

Moderna Reports Q1 Revenue of $389M

2026-05-01

07:10:00

Company Targets 10% Revenue Growth for 2026

2026-04-21 (ET)

2026-04-21

19:10:00

Moderna Launches Phase 3 Trial for H5 Influenza Vaccine

2026-04-21

09:50:00

Moderna's mCOMBRIAX Vaccine Approved by EU

2026-04-18 (ET)

2026-04-18

07:30:00

Sanofi's Nuvaxovid Vaccine Shows Lower Reactogenicity than Moderna's

2026-04-17 (ET)

2026-04-17

15:10:00

Moderna to Present mRNA-4359 Data at Cancer Research Meeting

2026-04-13 (ET)

2026-04-13

14:40:00

Moderna Shares Rise 1.11% to $51.52

News

moomoo

PinnedMODERNA REPORTS Q1 REVENUE OF $400 MILLION, EXCEEDING IBES ESTIMATE OF $228 MILLION

moomoo

PinnedMODERNA Q1 EPS at USD -3.4, Beating IBES Estimate of USD -3.96

seekingalpha

04-30seekingalpha

PinnedModerna Set to Report Q1 Earnings Amid Revenue Concerns

moomoo

PinnedModerna Executive States Company is Seeking FDA Guidance on Resuming US Filing for Flu-COVID Combination Vaccine

stocktwits

12:10 PMstocktwits

Moderna Targets 10% Revenue Growth for FY 2026

Fool

Atlassian Shares Surge 25% on AI-Driven Revenue Growth

20 Analyst Rating

Wall Street analysts forecast MRNA stock price to rise

1 Buy

16 Hold

3 Sell

Hold

Current: 0.000

Low

17.00

Averages

32.47

High

63.00

Current: 0.000

Low

17.00

Averages

32.47

High

63.00

BofA

Alex Stranahan

Underperform

maintain

$31 -> $32

AI Analysis

2026-05-01

New

Reason

BofA

Alex Stranahan

Price Target

$31 -> $32

AI Analysis

2026-05-01

New

maintain

Underperform

Reason

BofA analyst Alex Stranahan raised the firm's price target on Moderna to $32 from $31 and keeps an Underperform rating on the shares after the company reported better-than-expected Q1 revenue of $389M. The company had a "solid" Q1, but growth depends on uptake and oncology data, the analyst tells investors.

RBC Capital

Sector Perform

maintain

$30 -> $35

2026-04-07

Reason

RBC Capital

Price Target

$30 -> $35

2026-04-07

maintain

Sector Perform

Reason

RBC Capital raised the firm's price target on Moderna to $35 from $30 and keeps a Sector Perform rating on the shares as part of the firm's broader research note previewing Q1 results in Biotech. Seasonal headwinds around gross/net, reimbursement resets, and fewer selling days may be exacerbated in Q1 by weather impact, particularly for launching and in-clinic products, but the robust return of M&A, coupled with clarity on limited tariff/Most Favored Nation drug pricing impacts, could help offset both this and broader macro volatility while keeping sector perceptions favorable, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MRNA

Unlock Now

Valuation Metrics

The current forward P/E ratio for Moderna Inc (MRNA.O) is 23.04, compared to its 5-year average forward P/E of -0.80. For a more detailed relative valuation and DCF analysis to assess Moderna Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-0.80

Current PE

23.04

Overvalued PE

13.62

Undervalued PE

-15.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-2.65

Current EV/EBITDA

-5.85

Overvalued EV/EBITDA

6.94

Undervalued EV/EBITDA

-12.25

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

6.50

Current PS

7.17

Overvalued PS

9.13

Undervalued PS

3.87

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

what stocks trending today?

Intellectia · 46 candidates

Region: USPrice Change Pct: >= $0.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA5, PriceBelowMA5Is Trending: True

Ticker

Name

Market Cap$

Xerox Holdings Corp

205.32M

Skillz Inc

90.17M

Ginkgo Bioworks Holdings Inc

464.43M

Eli Lilly and Co

804.24B

Bakkt Inc

240.22M

Hyatt Hotels Corp

14.96B

Technical Analysis on vaccine

Intellectia · 6 candidates

Market Cap: >= 2.00BSector: Healthcare, Healthcare Services & Equipment, Pharmaceuticals & Medical ResearchThemes: BiotechRsi Category: moderateMoving Average Relationship: PriceAboveMA20Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Biogen Inc

26.91B

Moderna Inc

21.65B

Illumina Inc

20.18B

Incyte Corp

19.29B

Exelixis Inc

11.08B

CRISPR Therapeutics AG

5.56B

Day trading picks

Intellectia · 115 candidates

Price: $5.00 - $100.00Relative Vol: >= 2List Exchange: XNYS, XNAS, XASEMin5 Price Change Pct: $0.50 - $5.00Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Rigetti Computing Inc

6.58B

Redwire Corp

2.06B

Intuitive Machines Inc

5.98B

Dow Inc

25.62B

AXT Inc

4.59B

Sharplink Inc

1.58B

provide the best 3 stocks

Intellectia · 20 candidates

Price: $20.00 - $80.00List Exchange: XNYS, XNASIs Optionable: TrueOption Iv Rank: 50 - 80Is Index Component: GSPC, NDXMonthly Average Dollar Volume: >= 5,000,000

Ticker

Name

Market Cap$

Intel Corp

309.42B

Verizon Communications Inc

201.52B

Comcast Corp

101.86B

Trade Desk Inc

9.81B

Coca-Cola Co

336.50B

PayPal Holdings Inc

41.37B

find specific stocks

Intellectia · 20 candidates

Price: $20.00 - $80.00List Exchange: XNYS, XNASIs Optionable: TrueOption Iv Rank: 50 - 80Is Index Component: GSPC, NDXMonthly Average Dollar Volume: >= 5,000,000

Ticker

Name

Market Cap$

Intel Corp

309.42B

Verizon Communications Inc

201.52B

Coca-Cola Co

336.50B

Comcast Corp

101.86B

Boston Scientific Corp

91.07B

PayPal Holdings Inc

41.37B

us stocks and ETFs

Intellectia · 56 candidates

Region: USPrice: $10.00 - $150.00Beta: HighRiskList Exchange: XNYS, XNAS, XASEMin5 Price Change Pct: $0.40 - $2.50Monthly Average Dollar Volume: >= 5,000,000

Ticker

Name

Market Cap$

Marvell Technology Inc

79.99B

Shopify Inc

165.07B

Ondas Inc

4.73B

Barrick Mining Corp

72.21B

Roblox Corp

41.93B

Moderna Inc

21.05B

what stock should I buy rn

Intellectia · 7 candidates

Price: $10.00 - $80.00List Exchange: XNYS, XNASMoving Average Relationship: PriceAboveMA20Month Price Change Pct: $5.00 - $40.00Is Index Component: GSPC, NDXOne Week Predict Return: 0.0% - 100.0%Monthly Average Dollar Volume: >= 3,000,000

Ticker

Name

Market Cap$

LyondellBasell Industries NV

23.95B

Dow Inc

26.96B

Occidental Petroleum Corp

57.61B

MGM Resorts International

9.29B

Corteva Inc

53.63B

PayPal Holdings Inc

40.84B

what about for short term profit

Intellectia · 11 candidates

Price: $5.00 - $100.00List Exchange: XNYS, XNASMoving Average Relationship: PriceAboveMA20Month Price Change Pct: >= $8.00Is Index Component: GSPC, NDXMonthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Dow Inc

26.96B

LyondellBasell Industries NV

23.95B

Occidental Petroleum Corp

57.61B

Caesars Entertainment Inc

5.78B

EQT Corp

40.39B

Edwards Lifesciences Corp

49.14B

stocks on a uptrend

Intellectia · 15 candidates

Market Cap: >= 5.00BList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Quarter Price Change Pct: >= $60.00Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Immunitybio Inc

9.25B

Applied Optoelectronics Inc

7.50B

AstraZeneca PLC

312.56B

Moderna Inc

22.83B

Vicor Corp

9.22B

Enlight Renewable Energy Ltd

10.27B

What is the number one earner today?

Intellectia · 24 candidates

Market Cap: >= 10.00BPrice: >= $5.00Volume: >= 2,000,000Price Change Pct: >= $5.00List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Coinbase Global Inc

48.16B

Strategy Inc

44.28B

IREN Ltd

12.89B

AST SpaceMobile Inc

35.41B

Nebius Group NV

21.96B

Moderna Inc

19.68B

Whales Holding MRNA

Himension Capital (Singapore) Pte Ltd

Y-Intercept (Hong Kong) Limited

Two Sigma Investments, LP

Banque Pictet & Cie SA

Aquatic Capital Management LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Moderna Inc (MRNA) stock price today?

The current price of MRNA is 44.5964 USD — it has decreased -2.93

What is Moderna Inc (MRNA)'s business?

Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).

What is the price predicton of MRNA Stock?

Wall Street analysts forecast MRNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRNA is32.47 USD with a low forecast of 17.00 USD and a high forecast of 63.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Moderna Inc (MRNA)'s revenue for the last quarter?

Moderna Inc revenue for the last quarter amounts to 678.00M USD, decreased -29.81

What is Moderna Inc (MRNA)'s earnings per share (EPS) for the last quarter?

Moderna Inc. EPS for the last quarter amounts to -2.11 USD, decreased -26.99

How many employees does Moderna Inc (MRNA). have?

Moderna Inc (MRNA) has 4700 emplpoyees as of May 01 2026.

What is Moderna Inc (MRNA) market cap?

Today MRNA has the market capitalization of 18.22B USD.